Intravenous Pantoprazole Dosing for an 11-Year-Old
For an 11-year-old child, administer intravenous pantoprazole at 40 mg once daily, infused over 2 to 15 minutes, based on established pediatric pharmacokinetic data showing similar drug disposition to adults in children aged 2 to 16 years. 1
Dosing Recommendations
The standard dose is 40 mg IV once daily for children aged 2 to 16 years, as pharmacokinetic studies demonstrate that this age group achieves similar plasma concentrations and area under the curve values as adults receiving the same dose 1
Weight-based dosing of 0.8 to 1.6 mg/kg IV has been studied and found safe in children ages 2 to 16 years, though fixed 40 mg dosing is more commonly used in clinical practice 1
For an average 11-year-old (typically 30-40 kg), the 40 mg fixed dose falls within the appropriate weight-based range and provides effective acid suppression 1
Administration Details
Infuse over 2 to 15 minutes—both durations show equivalent safety and tolerability profiles with no significant differences in phlebitis, infiltration, pain, or burning 2
The 2-minute infusion may be preferred for time efficiency without compromising patient comfort or safety 2
Administer once daily, as the antisecretory effect persists beyond 24 hours regardless of dose (20-120 mg tested) 3
Duration and Monitoring
Treatment duration typically ranges from 7 to 10 days for acute management of GERD with erosive esophagitis, based on the transition studies from oral to IV formulations 3
Patients receiving ≥4 days of IV pantoprazole show higher incidence rates of vomiting, diarrhea, hypokalemia, hyponatremia, and abdominal distension compared to shorter courses 4, 5
Monitor electrolytes (potassium, sodium) during treatment, particularly if duration extends beyond 4 days, as hypokalemia (IR 195-203 per 1000 person-years) and hyponatremia (IR 183-205 per 1000 person-years) are among the most common adverse events 4, 5
Important Clinical Considerations
CYP2C19 metabolizer status significantly affects clearance: extensive metabolizers with only one functional allele show statistically different drug exposure compared to those with two functional alleles 1
Presence of systemic inflammatory response syndrome (SIRS), hepatic dysfunction, or concomitant CYP2C19 inhibitors can decrease pantoprazole clearance by 50-66%, though these conditions are less common in typical 11-year-old patients 6
Children aged 6 months to 5 years demonstrate faster clearance than adults, but by age 11, pharmacokinetics approximate adult values 6
Safety Profile
Common adverse events include headache, diarrhea, constipation, nausea, vomiting, and abdominal distension, occurring in up to 14% of pediatric patients 7
All adverse events in pediatric studies were mild in severity and well-tolerated 1
Real-world data from 1,879 infants and 981 toddlers confirm the safety profile is consistent with known pantoprazole risks 4, 5
Critical Pitfall to Avoid
- Do not use adult 80 mg dosing without specific indication (such as pathological hypersecretory conditions like Zollinger-Ellison syndrome), as standard GERD treatment requires only 40 mg daily in this age group 3